• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Levothyroxine Dosing for Thyroid-Stimulating Hormone Suppression in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy.

作者信息

Kim Mijin

机构信息

Department of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.

出版信息

Endocrinol Metab (Seoul). 2024 Aug;39(4):576-578. doi: 10.3803/EnM.2024.401. Epub 2024 Aug 26.

DOI:10.3803/EnM.2024.401
PMID:39223872
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11375302/
Abstract
摘要

相似文献

1
Levothyroxine Dosing for Thyroid-Stimulating Hormone Suppression in Patients with Differentiated Thyroid Cancer after Total Thyroidectomy.全甲状腺切除术后分化型甲状腺癌患者促甲状腺激素抑制的左甲状腺素剂量
Endocrinol Metab (Seoul). 2024 Aug;39(4):576-578. doi: 10.3803/EnM.2024.401. Epub 2024 Aug 26.
2
Adequate Dose of Levothyroxine for Thyroid-Stimulating Hormone Suppression after Total Thyroidectomy in Patients with Differentiated Thyroid Cancer.分化型甲状腺癌患者全甲状腺切除术后甲状腺刺激素抑制的左甲状腺素适宜剂量。
Endocrinol Metab (Seoul). 2024 Aug;39(4):615-621. doi: 10.3803/EnM.2023.1896. Epub 2024 Aug 7.
3
Thyroid Stimulating Hormone Suppression in the Long-term Follow-up of Differentiated Thyroid Cancer.分化型甲状腺癌长期随访中的促甲状腺激素抑制
Clin Oncol (R Coll Radiol). 2017 May;29(5):325-328. doi: 10.1016/j.clon.2016.12.011. Epub 2016 Dec 30.
4
Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.甲状腺机能减退症分化型甲状腺癌患者左甲状腺素治疗期间 TSH 水平的变化：对剂量调整的影响。
J Endocrinol Invest. 2019 Dec;42(12):1485-1490. doi: 10.1007/s40618-019-01074-x. Epub 2019 Jun 15.
5
Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.影响甲状腺乳头状癌术后患者促甲状腺激素抑制疗效的因素：一项回顾性队列研究
BMC Surg. 2024 May 3;24(1):133. doi: 10.1186/s12893-024-02426-y.
6
Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.分化型甲状腺癌患者接受促甲状腺激素抑制治疗后的命名困难：一项前瞻性队列研究。
Endocrine. 2019 Aug;65(2):327-337. doi: 10.1007/s12020-019-01943-8. Epub 2019 May 5.
7
Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.左甲状腺素对分化型甲状腺癌患者甲状腺球蛋白的抑制作用
J Clin Endocrinol Metab. 1999 Dec;84(12):4549-53. doi: 10.1210/jcem.84.12.6190.
8
Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.分化型甲状腺癌的促甲状腺激素抑制治疗：T3/T4联合治疗方法的作用
Head Neck. 2017 Dec;39(12):2567-2572. doi: 10.1002/hed.24926. Epub 2017 Sep 27.
9
Adequacy of TSH suppression by L-thyroxine administration in thyroid cancer patients after total thyroidectomy.甲状腺癌患者全甲状腺切除术后左甲状腺素给药对促甲状腺激素抑制的充分性。
J Endocrinol Invest. 1986;9 Suppl 4:77-88.
10
Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy.甲状腺机能减退症患儿在左甲状腺素治疗期间的三碘甲状腺原氨酸水平。
Front Endocrinol (Lausanne). 2024 Aug 14;15:1443394. doi: 10.3389/fendo.2024.1443394. eCollection 2024.

本文引用的文献

1
Adequate Dose of Levothyroxine for Thyroid-Stimulating Hormone Suppression after Total Thyroidectomy in Patients with Differentiated Thyroid Cancer.分化型甲状腺癌患者全甲状腺切除术后甲状腺刺激素抑制的左甲状腺素适宜剂量。
Endocrinol Metab (Seoul). 2024 Aug;39(4):615-621. doi: 10.3803/EnM.2023.1896. Epub 2024 Aug 7.
2
Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study).促甲状腺激素抑制对甲状腺叶切除术患者生活质量的影响：低至中风险甲状腺癌患者多中心随机对照试验的中期分析（MASTER研究）
Ann Surg Treat Res. 2024 Jan;106(1):19-30. doi: 10.4174/astr.2024.106.1.19. Epub 2023 Dec 28.
3
Levothyroxine Therapy in Thyrodectomized Patients.甲状腺切除术患者的左甲状腺素治疗。
Front Endocrinol (Lausanne). 2021 Jan 29;11:626268. doi: 10.3389/fendo.2020.626268. eCollection 2020.
4
Optimizing Levothyroxine Dose Adjustment After Thyroidectomy With a Decision Tree.基于决策树优化甲状腺切除术后左甲状腺素剂量调整
J Surg Res. 2019 Dec;244:102-106. doi: 10.1016/j.jss.2019.06.025. Epub 2019 Jul 4.
5
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.2015年美国甲状腺协会成人甲状腺结节和分化型甲状腺癌管理指南：美国甲状腺协会甲状腺结节和分化型甲状腺癌指南工作组
Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020.
6
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.分化型甲状腺癌治疗后的长期结局：1987 - 2012年NTCTCS登记分析
J Clin Endocrinol Metab. 2015 Sep;100(9):3270-9. doi: 10.1210/JC.2015-1346. Epub 2015 Jul 14.
7
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.对于美国甲状腺协会（ATA）低风险和中风险的分化型甲状腺癌患者，促甲状腺激素抑制治疗虽不会降低复发风险，但会增加骨质疏松症的风险。
Thyroid. 2015 Mar;25(3):300-7. doi: 10.1089/thy.2014.0287. Epub 2014 Dec 16.
8
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.甲状腺功能减退症治疗指南：由美国甲状腺协会甲状腺激素替代特别工作组制定。
Thyroid. 2014 Dec;24(12):1670-751. doi: 10.1089/thy.2014.0028.
9
Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma.中强度 vs 严格 TSH 抑制对晚期分化型甲状腺癌生存的影响。
Clin Endocrinol (Oxf). 2012 Apr;76(4):586-92. doi: 10.1111/j.1365-2265.2011.04272.x.
10
Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.分化型甲状腺癌中促甲状腺激素抑制治疗的获益与不良反应风险。
Thyroid. 2010 Feb;20(2):135-46. doi: 10.1089/thy.2009.0311.